Oragenics, Inc. (OGEN) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Oragenics, Inc. on September 1, 2025. The report discloses a corporate governance event: the appointment of a new member to the Board of Directors effective September 1, 2025.
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on the appointment of a director and associated compensation.
Material Changes
The primary material change is the addition of Ms. Natasha Giordano to the Board of Directors. Ms. Giordano brings extensive experience in pharmaceutical commercialization and healthcare management, having previously served as CEO of PLx Pharma Inc., Healthcare Corporation of America, and Xanodyne Pharmaceuticals, Inc.
Compensation and Governance Details
- Appointment: Ms. Giordano was appointed to the Board effective September 1, 2025.
- Compensation: Under the non-employee director compensation program, she will receive an annual base fee of $45,000. For the partial year of 2025, the Board agreed to pay $3,750 per month for September, October, November, and December.
- Related Party Transactions: The filing states there are no related party transactions requiring disclosure under Item 404(a) of Regulation S-K.
- Future Action: Ms. Giordano has agreed to stand for re-election at the next annual meeting of shareholders.
Investor Verification Checklist
- Verify the effective date of Ms. Giordano's board appointment (September 1, 2025).
- Confirm the pro-rated compensation structure ($3,750/month for the remainder of 2025).
- Review Ms. Giordano's prior board service and executive roles to assess potential conflicts of interest or strategic alignment.
- Note that no financial results or guidance are included in this specific filing.